Peptide Association
Start Your Consultation
All peptides
OncologyFDA Approved

177Lu-PSMA-617 (Pluvicto)

Intravenous
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

177Lu-PSMA-617 is a radioligand therapeutic consisting of a small peptide-based ligand targeting prostate-specific membrane antigen (PSMA) conjugated to the beta-emitting radioisotope lutetium-177. The peptide component binds selectively to PSMA, a transmembrane protein highly expressed on prostate cancer cells, enabling targeted delivery of cytotoxic radiation to tumor sites while sparing normal tissues.

Mechanism of Action

It is indicated for treatment of metastatic castration-resistant prostate cancer in patients previously treated with androgen receptor pathway inhibition and taxane-based chemotherapy. The targeting moiety is derived from a urea-based peptidomimetic scaffold optimized for PSMA affinity.

Research Summary & Key Findings

177Lu-PSMA-617 received FDA approval in March 2022 based on the VISION trial (NEJM 2021), a randomized phase 3 study demonstrating significant improvements in overall survival (median 15.3 vs 11.3 months) and radiographic progression-free survival compared to standard of care alone. The trial enrolled 831 patients with PSMA-positive metastatic castration-resistant prostate cancer. Treatment-related adverse events included myelosuppression and dry mouth, with the majority of events being grade 1 or 2.

Clinical Status

FDA Approved

177Lu-PSMA-617 (Pluvicto) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intravenous

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Oncology

Carfilzomib (Kyprolis)

FDA Approved

A tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...

View details

Bortezomib (Velcade)

FDA Approved

A modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...

View details

Lutetium-177 dotatate (Lutathera)

FDA Approved

A radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...

View details

Leuprolide (Lupron) - Oncology

FDA Approved

A GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...

View details

Start Your Consultation

Get an AI-proposed 177Lu-PSMA-617 (Pluvicto) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply 177Lu-PSMA-617 (Pluvicto).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.